Recruiting

G-CSF Mobilized Leukapheresis for Improved Stem Cell Selection in Transplantation

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to observe how G-CSF mobilized leukapheresis can help improve the selection of stem cells for transplantation by providing a source of primitive hematopoietic cells for various laboratory studies.

What is being collected

Drug Data

Collected from today forward - Prospective
Drug
Who is being recruted

Immune System Diseases

+ Graft vs Host Disease

From 18 to 60 Years
+21 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Case-Only

Examining characteristics of individuals with a disease in order to identify genetic or environmental factors contributing to the condition.
Observational
Study Start: March 1996
See protocol details

Summary

Principal SponsorNational Heart, Lung, and Blood Institute (NHLBI)
Study ContactRichard A Gustafson, R.N.More contacts
Last updated: June 30, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: March 18, 1996

Actual date on which the first participant was enrolled.

The NHLBI Stem Cell Transplantation program is exploring ways to make allogeneic transplantation safer and more widely applicable. Prior NHLBI transplant protocols have evaluated the strategy of using T cell depleted marrow transplants followed by delayed lymphocyte add-back to control or prevent GVHD while conserving useful donor immune function against residual leukemia and infectious agents. Over the past ten years, a number of increasingly efficient methods have been used to deplete T cells but retain stem cells, and we have shown the safety and utility of the delayed T cell add-back approach. We have also found a positive relationship between the administration of higher CD34+ cell doses and outcome. Investigation of highly purified grafts with the add-back of specific T cell populations is ongoing, and the ability to test new purification approaches and devices on clinical-scale PBSC products is critical to the continued development of new transplantation approaches in our program. This requires testing the approaches on G-CSF mobilized PBSCs collected by apheresis from healthy donors since this is the cell source that will be used in all clinical allogeneic transplantation protocols in our program. Therefore, the primary intent of this protocol is to provide a mechanism for mobilizing, collecting, storing, and analyzing G-CSF mobilized apheresis samples from healthy volunteers. Cells will be used to develop a method of processing the cells that are collected after stimulation with G-CSF, by removing the lymphocytes, which can mediate GVHD while retaining the stem cells which are necessary for hematopoietic reconstitution. At the same time, we will study whether G-CSF administration has an effect on lymphocyte, function which may influence the immune reactions occurring in allogeneic bone marrow transplantation. Furthermore, the CD34+ cells collected will be a valuable resource for experimental studies of lymphocyte-stem cell interactions in our laboratory.

NCT00001529
Principal SponsorNational Heart, Lung, and Blood Institute (NHLBI)
Study ContactRichard A Gustafson, R.N.More contacts
Last updated: June 30, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

500 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Case-only

These studies focus only on individuals who have a specific disease. Researchers examine patterns—often genetic or environmental—to uncover what might be linked to the condition.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 60 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Immune System DiseasesGraft vs Host Disease

Criteria

11 inclusion criteria required to participate
Antecubital veins must be adequate for peripheral access during apheresis. Potential participants must be screened by an apheresis nurse to check venous access before protocol entry

Female subjects should not be lactating

Healthy female subjects of childbearing age should have a negative serum pregnancy test with one week of beginning G-CSF administration

Healthy individual aged 18 to 60 years

Show More Criteria

10 exclusion criteria prevent from participating
Active or moderate-to-severe autoimmune disease that is currently treated or expected to require immunosuppressive therapy. Candidates with stable, well-controlled mild autoimmune disease may be considered on a case-by-case basis

Active or recent malignancy within the past 5 years. Individuals with remote ( > 5 years) histories of low-risk malignancies in remission (e.g., localized prostate cancer) or treated basal cell carcinoma may be included

Active viral, bacterial, fungal or parasite infection

Administration of NSAID within. 5-7 days of starting the protocol, depending on drug half-life

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

National Institutes of Health Clinical Center

Bethesda, United StatesOpen National Institutes of Health Clinical Center in Google Maps
Recruiting
One Study Center